IlDong Pharmaceutical
CompanySouth KoreaFounded 1941
IlDong Pharmaceutical develops 3 assets, the furthest approved (ezetimibe in heterozygous familial hypercholesterolemia). Mostly small molecule acting on lipid and ceramide metabolism, HMGCR and AMPK signalling; based in South Korea, founded in 1941.
- 3
- Assets
- Furthest
- Approved
- 10
- Trials
- 2
- Signals
Pipeline
3Inhibits ATP citrate lyase to reduce cholesterol biosynthesis
Approved, Small molecule, AMPK signalling, Lipid and ceramide metabolism, heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia
PPAR alpha agonist regulating lipid metabolism
Approved, Small molecule, Lipid and ceramide metabolism, PPARA, dyslipidemia, hypercholesterolemia
HMG-CoA reductase inhibitor lowering LDL cholesterol.
Approved, Small molecule, Lipid and ceramide metabolism, SLC5A2, acute coronary syndrome (Phase 3), atherosclerosis (Phase 3)
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms9
- Trials10
- Signals8
- Similar companies6
Updated 9 Oct 2026 · 183 sources